Subscribe
Pembrolizumab is a humanized antibody that exerts dual blockade of the immune checkpoint receptor programmed death-1 (PD-1). It has demonstrated robust antitumor activity and acceptable tolerability in several tumors, including melanoma and lung cancer. The KEYNOTE-012 trial is an ongoing, [ Read More ]
Nivolumab is a fully human monoclonal antibody that inhibits the programmed death-1 (PD-1) immune checkpoint receptor to restore T-cell antitumor immune responses, and has shown clinical activity in metastatic renal-cell carcinoma (mRCC). Motzer and colleagues presented updated data on overall [ Read More ]
The human monoclonal antibody MPDL3280A is directed against the immune checkpoint receptor programmed death-1 (PD-1) ligand 1(PD-L1), disrupting PD-L1 binding to its receptors PD-1 and B7.1. A phase 1 study evaluated the safety and efficacy of MPDL3280A in several cancer [ Read More ]
Treatments are limited for patients with metastatic urothelial bladder cancer. MPDL3280A is a human monoclonal antibody that is directed against the immune checkpoint receptor programmed death-1 (PD-1) ligand 1 (PD-L1), disrupting PD-L1 binding to its receptors PD-1 and B7.1. At [ Read More ]
Ipilimumab is an approved immunotherapy that blocks the function of the immune checkpoint modulator CTLA-4 (cytotoxic T-lymphocyte antigen-4) to augment T-cell antitumor immune responses. The multicenter, randomized, double-blind, phase 3 clinical trial CA184-043 evaluated the efficacy of radiotherapy followed by [ Read More ]
Pembrolizumab is a humanized high-affinity antibody that exerts dual-ligand blockade of the immune checkpoint receptor programmed death-1 (PD-1). The KEYNOTE-001 trial is a phase 1 nonrandomized dose-escalation trial that tested pembrolizumab in 5 dose/schedule cohorts that included 135 ipilimumab-naïve (IPI-N) [ Read More ]
Nivolumab is a fully human monoclonal antibody that is directed toward the immune checkpoint receptor programmed death-1 (PD-1). A phase 1 dose-escalation/cohort expansion study demonstrated encouraging antitumor activity and tolerability in 107 ipilimumab-naïve previously treated patients with advanced melanoma; patients [ Read More ]
The treatment options for patients with advanced melanoma that have progressed on approved agents are limited. Nivolumab is a fully human monoclonal antibody that is directed toward the immune checkpoint receptor programmed death-1 (PD-1), which has demonstrated durable antimelanoma activity [ Read More ]
Despite major treatment advances made in advanced non–small-cell lung cancer (NSCLC), the prognosis remains poor. The 1-year overall survival rate with standard first-line therapy of platinum-based doublet chemotherapy (PT-DC) is approximately 30% to 40% for patients with advanced NSCLC, with [ Read More ]
Androgen-deprivation therapy (ADT) is an integral component of the management of patients with hormone-naïve metastatic prostate cancer (HN-mPCa). There is some evidence implicating ADT in immune regulation by increasing the thymic output of T-cells, antigen-specific T-cell responses, and infiltration of [ Read More ]